Novartis announced on Monday, November 10 2025, that it has opened a new 10,000‑square‑foot manufacturing facility in Carlsbad, California, dedicated to producing cancer treatments. The facility is part of the company’s pledge to invest billions into building U.S. sites.
The new plant expands Novartis’s U.S. manufacturing footprint, reducing reliance on overseas production and improving supply‑chain resilience for its oncology portfolio. It also supports the company’s strategy to focus on high‑margin specialty medicines.
The Carlsbad facility will support production of key oncology products, underscoring Novartis’s commitment to meeting growing demand for its cancer therapies and to maintaining a robust U.S. supply chain amid regulatory and trade uncertainties.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.